DeepMed Research

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Drug: Hydrocodone ER
Drug: Placebo

First Posted Date: 2013-08-14

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 182

Registration Number: NCT01922739

Locations: 🇺🇸
Teva Investigational Site 10426, Mobile, Alabama, United States
🇺🇸
Teva Investigational Site 10425, Carmichael, California, United States
🇺🇸
Teva Investigational Site 10370, Los Angeles, California, United States

and more 58 locations

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: CEP-37440

First Posted Date: 2013-08-14

Last Posted Date: 2021-11-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 32

Registration Number: NCT01922752

Locations: 🇺🇸
Teva Investigational Site 10686, San Antonio, Texas, United States
🇺🇸
Teva Investigational Site 10689, Chicago, Illinois, United States
🇺🇸
Teva Investigational Site 10687, Philadelphia, Pennsylvania, United States

Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects

Phase 1

Completed

Conditions: Cognitive Impairment

Interventions: Drug: CEP-26401
Drug: Placebo
Drug: donepezil hydrochloride
Drug: modafinil

First Posted Date: 2013-07-19

Last Posted Date: 2014-04-03

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 40

Registration Number: NCT01903824

Locations: 🇳🇱
Teva Investigational Site 38051, Leiden, Netherlands

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Albuterol Spiromax
Drug: ProAir HFA
Drug: Placebo

First Posted Date: 2013-07-15

Last Posted Date: 2022-01-26

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 61

Registration Number: NCT01899144

Locations: 🇺🇸
Teva Investigational Site 10610, Costa Mesa, California, United States
🇺🇸
Teva Investigational Site 10598, Birmingham, Alabama, United States
🇺🇸
Teva Investigational Site 10597, San Jose, California, United States

and more 19 locations

Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

Phase 2

Completed

Conditions: Cocaine Addiction

Interventions: Drug: TV-1380 150 mg
Drug: TV-1380 300 mg
Drug: Placebo

First Posted Date: 2013-06-26

Last Posted Date: 2015-11-05

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 208

Registration Number: NCT01887366

Locations: 🇺🇸
Teva Investigational Site 10665, Oceanside, California, United States
🇺🇸
Teva Investigational Site 10745, Las Vagas, Nevada, United States
🇺🇸
Teva Investigational Site 10667, Marlton, New Jersey, United States

and more 16 locations

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Rasagiline

First Posted Date: 2013-06-18

Last Posted Date: 2013-12-20

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 64

Registration Number: NCT01879748

Locations: 🇺🇸
Teva Investigational Site 10738, Glendale, California, United States

Safety and Tolerability of Glatiramer Acetate

Phase 3

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: GA 20 mg/mL
Drug: GA 40 mg/mL

First Posted Date: 2013-06-10

Last Posted Date: 2016-01-14

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 209

Registration Number: NCT01874145

Locations: 🇺🇸
Teva Investigational Site 10732, Baltimore, Maryland, United States
🇺🇸
Teva Investigational Site 10726, Great Falls, Montana, United States
🇺🇸
Teva Investigational Site 10720, Phoenix, Arizona, United States

and more 32 locations

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Phase 3

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Albuterol Spiromax®

First Posted Date: 2013-05-20

Last Posted Date: 2015-06-08

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 317

Registration Number: NCT01857323

Locations: 🇺🇸
Teva Investigational Site 10641, Overland Park, Kansas, United States
🇺🇸
Teva Investigational Site 10627, St. Louis, Missouri, United States
🇺🇸
Teva Investigational Site 10626, Medford, Oregon, United States

and more 27 locations

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Albuterol Spiromax®
Drug: ProAir® HFA

First Posted Date: 2013-05-01

Last Posted Date: 2013-11-14

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 15

Registration Number: NCT01844401

Locations: 🇺🇸
Teva Investigational Site 10538, Costa Mesa, California, United States

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Phase 1

Completed

Conditions: Hematologic Malignancies
Solid Tumors

Interventions: Drug: omacetaxine mepesuccinate

First Posted Date: 2013-05-01

Last Posted Date: 2015-01-30

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 6

Registration Number: NCT01844869

Locations: 🇳🇱
Teva Investigational Site 38045, Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy